MSA and Alpha synuclein oligomers, Epigallocatechin-gallate Relationship
Formation of toxic α-synuclein oligomers appears to be a key underlying
pathological mechanism of synucleinopathies such as Parkinson's disease or
multiple system atrophy (MSA).
Given that Epigallocatechin-gallate has been shown to inhibit
α-synuclein aggregation, it might represent a causal treatment option.
Therefore, we set out to evaluate the safety, tolerability and a potential
disease-modifying effect of Epigallocatechin-gallate in patients with MSA after
48 weeks of treatment.
For more information, please visit article
The PROMESA-protocol: progression rate
of multiple system atrophy under EGCG supplementation as anti-aggregation-approach.
Posts
No comments:
Post a Comment